大行評級 | 野村:市傳美要求生物技術產業降對華依賴 料藥明生物(2269.HK)短期面臨壓力
格隆匯9月13日丨就市場傳出美國總統拜登將簽署一項行政命令以擴大美國的生物技術產業發展,以降低對中國於先進生物製造基礎設施的依賴,野村發表報告認爲,短期內可能對中國生物醫藥的委託開發製造(CDMO(Contract Development and Manufacturing Organization))參與者產生影響,美方或以類似早前發佈的芯片製造領域以行政命令作爲尖端領域的手段,與中國作戰略競爭。該行指,雖然從全球行業競爭的角度來看,藥明生物爲代表的中國生物CDMO行業仍然相對年輕及規模較小,但其在於新冠疫情環境下快速增長和效率表現令該行業備受關注。野村料中國生物醫藥行業,特別是藥明生物將面臨短期壓力。從長遠來看,該行建議投資者關注美方落實的行政命令的細節。該股現報53.9港元,總市值2299億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.